Amundi’s Novartis NVS Stock Holding History

Amundi’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,602	Closed	-$1.02M	–	2054
2023 Q4	$1.02M	Buy	+9,602	New	+$927K	﹤0.01%	1324

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amundi's NVS Position: Q1 2024 in Review

Amundi sold out of Novartis (NVS) in Q1 2024, closing a stake of 9,602 shares — an estimated $1.02M sold.

Amundi first reported a position in NVS in Q4 2023 and held it in 1 quarter. The position peaked at $1.02M in Q4 2023. 1,253 funds tracked by Wall St. Rank hold NVS as of Q1 2024.

Amundi reported no remaining Novartis position as of Q1 2024 after selling out during the quarter.
Amundi sold 9,602 Novartis shares in Q1 2024, an estimated $1.02M.
Amundi first reported a position in Novartis in Q4 2023 and held it in 1 quarter.
Amundi's Novartis position peaked at $1.02M in Q4 2023.
1,253 funds tracked by Wall St. Rank held Novartis as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.